The purpose of this study is to determine whether Adefovir Dipivoxil is effective and safe in
treatment of Chinese Patients with HBeAg positive Chronic Hepatitis B for 5 years.
Primary Outcomes
Measure: The log10 reduction in HBV DNA from baseline at week 12 between ADV 10mg and matching placebo Time: Week 12
Secondary Outcomes
Measure: The proportion of subjects with ALT normalisation Time: Week 52, 104, 156, 208, 260
Measure: log10 reduction in serum HBV DNA Time: Week 52, 104, 156, 208, 260
Measure: The proportion of subjects with HBV DNA 10(5) copies/mL or a 2 log10 reduction from Baseline HBV DNA level Time: Week 52, 104, 156, 208, 260
Measure: The proportion of subjects with HBeAg loss Time: Week 52, 104, 156, 208, 260
Measure: The proportion of subjects with HBeAg seroconversion Time: Week 52, 104, 156, 208, 260
Measure: The proportion of subjects developing N236T and A181V HBV DNA genotypic mutations associated with ADV resistance Time: Week 52, 104, 156, 208, 260
Measure: The proportion of subjects with HBV DNA undetectable (<300 copies/mL) Time: Week 52, 104, 156, 208, 260